Answer
Rifampicin reduces exposure to dolutegravir in Dovato through induction of UGT1A1 and CYP3A enzymes, decreasing AUC by 54%, maximum concentration by 43% and concentration at the end of the dosing interval by 72%.
Sources for this answer
- Dovato 50 mg/300 mg film-coated tabletsViiV Healthcare UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 17Document updated
Sources checked